NCT06827327

LC-Plasma for Preventing URTIs and Reducing Symptoms

A Randomized Controlled Trial Evaluating the Efficacy of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria in Preventing Upper Respiratory Tract Infections and Reducing Symptom Severity and Duration

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 637 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to evaluate the efficacy of the LC-Plasma in preventing upper respiratory tract infections (URTIs) in healthy volunteers. Researchers will compare LC-Plasma to placebo to see if LC-Plasma prevents URTIs. Participants will take a tablet containing LC-Plasma or placebo daily for 24 weeks.

Conditions

• Healthy Volunteer
• URTI

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LC-Plasma	1 tablet containing 50mg LC-Plasma is taken daily for 24 weeks
OTHER	Placebo	1 tablet containing 50mg MCC is taken daily for 24 weeks

Timeline

• Start date: 2025-03-28
• Primary completion: 2026-01-10
• Completion: 2026-01-10
• First posted: 2025-02-14
• Last updated: 2026-03-06

Locations

1 site across 1 country: Australia